Pharma & HealthcareTop Companies
Pharma & Healthcare

Top CGM Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

Industry

Pharma & Healthcare

Published

Feb 2026

Share:

Pharma & Healthcare

Top CGM Market Companies - Rankings, Profiles, Market Share, SWOT & Strategic Outlook

$3,590

Choose License Type

Only one user can use this report

Additional users can access this report

You can share within your company

Company Contents

Quick Facts & Snapshot

2025 Market Size (US$)
13.70 Billion
2026 Forecast (US$)
15.10 Billion
2032 Forecast (US$)
27.60 Billion
CAGR (2025-2032)
10.20%

Summary

The global continuous glucose monitoring (CGM) market is entering a scale-up phase, with leading CGM market companies leveraging advanced sensors, connectivity, and analytics to improve safety and therapeutic efficiency. The market is projected to grow from US$ 13.70 Billion in 2025 to US$ 27.60 Billion by 2032, reflecting a robust 10.20% CAGR.

2025 Revenue of Top CGM Suppliers
ReportMines Logo

Source: Secondary Information and ReportMines Research Team - 2026

Ranking Methodology

The ranking of CGM market companies is based on a composite scoring model that balances quantitative and qualitative indicators. Core criteria include 2025 CGM revenue, multi-year revenue growth, installed sensor base, and share of connected users. We also assess technology differentiation, such as factory calibration, sensor wear duration, interoperability with insulin pumps, and AI-driven decision support. Portfolio breadth across professional, real-time, and intermittently scanned CGM, plus coverage of Type 1, Type 2, and gestational use cases, is weighted significantly. Service and distribution capabilities, geographic reach, payer access, and ability to secure long-term contracts with health systems and payers further influence ranking. Finally, we consider evidence generation, clinical trial depth, regulatory track record, and the robustness of digital ecosystems. Scores are normalized, peer-benchmarked, and reviewed to ensure that both current scale and future competitiveness are reflected.

Top 10 Companies in CGM

1
Dexcom, Inc.
Dexcom G7, Dexcom G6, Dexcom Stelo (non-insulin users)
San Diego, USA
Real-time CGM for Type 1 and insulin-intensive Type 2 diabetes
Global market leader in stand-alone CGM systems with strong payor relationships and extensive clinical evidence
North America, Western Europe, rapidly expanding presence in Asia Pacific
4.20 Billion
Expanded non-adjunctive labeling, digital partnerships with telehealth platforms, targeted launches in emerging markets
2
Abbott Laboratories (FreeStyle Libre)
FreeStyle Libre 3, Libre 2, LibreView
Abbott Park, USA
Intermittently scanned CGM, integrated diabetes management platforms
Price-disruptive, volume-leading player with strong adherence in non-intensively treated Type 2 segment
Europe, North America, Latin America, selective penetration in Asia
4.00 Billion
Broadened reimbursement for Type 2 users, mobile app upgrades, integration with insulin delivery partners
3
Medtronic plc
Guardian Sensor 4, MiniMed 780G ecosystem
Dublin, Ireland
Integrated insulin pump-CGM systems, closed-loop solutions
Top integrated CGM player leveraging large installed insulin pump base and hospital relationships
North America, Europe, selected Asia Pacific markets
1.80 Billion
Algorithm enhancements, next-generation sensor pipeline, expanded hybrid closed-loop trials
4
Senseonics Holdings, Inc.
Eversense E3
Germantown, USA
Implantable, long-term CGM sensors
Niche innovator in long-wear implantable CGM with differentiated convenience for selected patient cohorts
USA, selected EU countries
0.25 Billion
Extended wear duration development, broader endocrinologist outreach, partnerships with specialty clinics
5
Roche Diabetes Care
Accu-Chek CGM platform, mySugr app suite
Basel, Switzerland
Connected diabetes ecosystem, CGM and SMBG integration
Strong integrated data and services player, leveraging long-standing presence in diabetes monitoring
Europe, Latin America, parts of Asia Pacific
0.60 Billion
Portfolio rationalization, enhanced data platforms, selective partnerships with payors and clinics
6
Ascensia Diabetes Care / PHC Group
Eversense (commercial partner), Contour portfolio
Basel, Switzerland
CGM for Type 1 and insulin-treated Type 2, legacy SMBG portfolio
Mid-sized player combining CGM innovation access with established distribution
Europe, North America, Japan
0.35 Billion
Expanded commercialization of Eversense, digital coaching integration, channel optimization
Collaborates closely with Senseonics to commercialize implantable CGM solutions
7
Ypsomed Holding AG
YpsoPump, mylife Loop ecosystem
Burgdorf, Switzerland
Insulin pumps integrated with third-party CGM systems
Specialist in interoperable pump platforms enabling flexible CGM partnerships
Europe, expanding in Asia Pacific
0.20 Billion
New integration agreements with leading CGM market companies, expansion of automated insulin delivery features
8
POCTech (Medtrum / related entities)
POCTech CT-100, Medtrum A7+ TouchCare
Nanjing, China
Cost-effective real-time CGM, integrated patch pumps
Price-competitive Asian challenger targeting underpenetrated, cost-sensitive markets
China, selected emerging markets
0.18 Billion
Pricing-led expansion, regulatory submissions outside China, partnerships with local hospitals
9
Nemaura Medical Inc.
sugarBEAT
Loughborough, UK
Non-invasive or minimally invasive CGM and metabolic monitoring
Emerging innovator with non-invasive value proposition for wellness and prediabetes segments
UK, early-stage entry in North America and Middle East
0.10 Billion
Pilot programs with wellness providers, refinement of patch technology, B2B partnerships
10
A. Menarini Diagnostics
GlucoMen Day CGM, regional co-branded solutions
Florence, Italy
Diabetes diagnostics, regional CGM distribution partnerships
Regional specialist leveraging strong physician relationships and multi-brand diabetes portfolio
Southern Europe, selected Eastern European markets
0.08 Billion
Regional distribution agreements, expanded physician education programs, integration with clinic information systems

Source: Secondary Information and ReportMines Research Team - 2026

Detailed Company Profiles

1

Dexcom, Inc.

Dexcom is a global CGM leader focused on real-time glucose monitoring and connected diabetes care for insulin-intensive patients.

Key Financials: 2025 CGM revenue US$ 4.20 Billion; estimated CGM revenue CAGR 2025-2032 around 10.20%.
Flagship Products: Dexcom G7, Dexcom G6, Dexcom Stelo
2025-2026 Actions: Expanded non-insulin user segment, strengthened cloud data platforms, deepened collaborations with insulin pump manufacturers.
Three-line SWOT: Technologically advanced sensor platform and strong brand loyalty; Premium pricing versus low-cost Asian rivals; Opportunity—large underpenetrated Type 2 and prediabetes populations globally.
Notable Customers: Kaiser Permanente, NHS England trusts, major U.S. commercial payors
2

Abbott Laboratories (FreeStyle Libre)

Abbott’s Diabetes Care business is a scale player in sensor-based glucose monitoring with a focus on intermittent scanning CGM.

Key Financials: 2025 CGM revenue US$ 4.00 Billion; strong double-digit Libre user base growth in Europe and North America.
Flagship Products: FreeStyle Libre 3, FreeStyle Libre 2, LibreView
2025-2026 Actions: Expanded reimbursement for Type 2 users, enhanced mobile apps, broadened integration with insulin dosing decision-support tools.
Three-line SWOT: High-volume, cost-efficient manufacturing and broad reimbursement; Perception of lower functionality versus full real-time CGM in some segments; Opportunity—expansion into non-insulin and wellness monitoring populations.
Notable Customers: German sickness funds, French social security system, U.S. Medicare beneficiaries
3

Medtronic plc

Medtronic is a diversified medtech major with CGM tightly integrated into its insulin pump and automated insulin delivery platforms.

Key Financials: 2025 CGM revenue US$ 1.80 Billion; CGM growth supported by increasing MiniMed 780G system adoption.
Flagship Products: Guardian Sensor 4, MiniMed 780G ecosystem
2025-2026 Actions: Accelerated rollout of advanced algorithms, invested in next-generation sensor chemistry, expanded clinical evidence for hybrid closed-loop systems.
Three-line SWOT: Large installed pump base and hospital relationships; CGM accuracy and user-experience historically lagged pure-play leaders; Opportunity—closed-loop adoption and new approvals in emerging markets.
Notable Customers: U.S. integrated delivery networks, major European university hospitals, private diabetes clinics
4

Senseonics Holdings, Inc.

Senseonics develops implantable, long-term CGM sensors designed for patients seeking fewer insertions and extended wear duration.

Key Financials: 2025 CGM revenue US$ 0.25 Billion; focused investment in R&D for 365-day sensor programs.
Flagship Products: Eversense E3
2025-2026 Actions: Scaled collaboration with Ascensia Diabetes Care, increased physician training, advanced trials for longer-wear implantable devices.
Three-line SWOT: Unique long-term implantable technology; Requires minor surgical procedure and skilled providers; Opportunity—specialized clinics and highly engaged Type 1 patient segments.
Notable Customers: Endocrinology specialty centers, U.S. private insurers, selected European diabetes clinics
5

Roche Diabetes Care

Roche Diabetes Care offers an integrated ecosystem combining CGM, SMBG, and digital apps for holistic diabetes management.

Key Financials: 2025 CGM revenue US$ 0.60 Billion; stable margins supported by broader diabetes solutions portfolio.
Flagship Products: Accu-Chek CGM platform, mySugr app suite
2025-2026 Actions: Advanced data integration with electronic health records, optimized channel mix, and expanded remote coaching pilots with health systems.
Three-line SWOT: Strong brand equity and data integration capabilities; CGM portfolio less visible than leading pure-play competitors; Opportunity—leveraging installed SMBG base to accelerate CGM conversion.
Notable Customers: European sickness funds, Latin American public health systems, private diabetes centers
6

Ascensia Diabetes Care / PHC Group

Ascensia is a global diabetes care player commercializing CGM technologies, including implantable solutions, through established distribution networks.

Key Financials: 2025 CGM revenue US$ 0.35 Billion; growing share from implantable CGM commercialization.
Flagship Products: Eversense (commercial partner), Contour portfolio
2025-2026 Actions: Expanded promotional focus on implantable CGM, integrated digital coaching, rationalized legacy SMBG SKUs in mature markets.
Three-line SWOT: Strong distribution and customer relationships; Dependence on partner pipeline for core CGM innovation; Opportunity—hybrid offerings combining SMBG and CGM in cost-sensitive markets.
Notable Customers: Pharmacies across Europe, Japanese hospitals, U.S. endocrinology networks
7

Ypsomed Holding AG

Ypsomed specializes in insulin delivery systems that integrate with leading CGM technologies to enable automated insulin delivery solutions.

Key Financials: 2025 CGM-related revenue US$ 0.20 Billion; revenue increasingly tied to interoperable pump ecosystems.
Flagship Products: YpsoPump, mylife Loop ecosystem
2025-2026 Actions: Secured new CGM integration partnerships, expanded automated dosing features, and broadened market access in Europe and Asia.
Three-line SWOT: Interoperable platform and agile development; Relatively small scale compared with global diabetes majors; Opportunity—growing demand for open, mix-and-match diabetes technology ecosystems.
Notable Customers: European diabetes centers, Swiss regional payors, select Asia Pacific clinics
8

POCTech (Medtrum / related entities)

POCTech and affiliated entities provide cost-efficient CGM systems and patch pumps targeting high-volume, price-sensitive diabetes populations.

Key Financials: 2025 CGM revenue US$ 0.18 Billion; strong domestic growth in China and early-stage exports.
Flagship Products: POCTech CT-100, Medtrum A7+ TouchCare
2025-2026 Actions: Scaled manufacturing capacity, pursued CE and FDA approvals, deepened collaborations with Chinese hospitals and insurers.
Three-line SWOT: Competitive pricing and local manufacturing scale; Limited global brand recognition; Opportunity—large untapped diabetic population in China and emerging markets.
Notable Customers: Chinese provincial hospitals, community health centers, emerging-market distributors
9

Nemaura Medical Inc.

Nemaura Medical is an emerging innovator developing non-invasive or minimally invasive CGM and metabolic monitoring wearables.

Key Financials: 2025 CGM revenue US$ 0.10 Billion; reinvests heavily in R&D and clinical validation programs.
Flagship Products: sugarBEAT
2025-2026 Actions: Launched pilot programs with wellness providers, refined user experience, and pursued regional regulatory submissions.
Three-line SWOT: Non-invasive proposition appealing to needle-averse users; Early-stage adoption and limited long-term data; Opportunity—prediabetes, corporate wellness, and consumer health channels.
Notable Customers: Corporate wellness programs, private clinics, early-adopter consumers
10

A. Menarini Diagnostics

A. Menarini Diagnostics is a regional diagnostics specialist offering CGM solutions and distribution services in European diabetes markets.

Key Financials: 2025 CGM revenue US$ 0.08 Billion; stable regional growth backed by multi-diagnostic portfolio.
Flagship Products: GlucoMen Day CGM, co-branded regional solutions
2025-2026 Actions: Expanded education for diabetologists, strengthened payer negotiations, and integrated data into clinic information systems.
Three-line SWOT: Strong local relationships and multichannel reach; Limited resources for large-scale global expansion; Opportunity—capturing CGM conversion in Southern and Eastern Europe.
Notable Customers: Italian regional health services, Spanish hospitals, Eastern European distributors

SWOT Leaders

Dexcom, Inc.

SWOT Snapshot

SWOT
Strengths

Market-leading accuracy, strong brand recognition, extensive clinical evidence, and deep integration with digital health ecosystems and insulin pumps.

Weaknesses

Premium pricing in many markets, reliance on a concentrated product portfolio, and exposure to reimbursement decisions in key countries.

Opportunities

Expansion into Type 2 and prediabetes populations, broader primary care adoption, and further penetration in Asia Pacific and Latin America.

Threats

Pricing pressure from low-cost competitors, rapid innovation cycles, cybersecurity risks, and potential tighter reimbursement in mature markets.

Abbott Laboratories (FreeStyle Libre)

SWOT Snapshot

SWOT
Strengths

High-volume manufacturing, attractive price point, broad reimbursement coverage, and strong brand recognition among Type 2 diabetics globally.

Weaknesses

Perceived as less feature-rich than full real-time CGM, limited integration in some pump ecosystems, and intense internal portfolio priorities.

Opportunities

Upselling users to advanced Libre versions, expansion into wellness and metabolic health, and scaling in emerging markets with payor partnerships.

Threats

Competition from both premium and budget CGM offerings, regulatory scrutiny on data privacy, and macroeconomic pressures on public healthcare budgets.

Medtronic plc

SWOT Snapshot

SWOT
Strengths

Large installed insulin pump base, strong hospital presence, and experience with automated insulin delivery and closed-loop systems.

Weaknesses

Historically slower sensor innovation cycles, complex product ecosystem, and dependence on integrated pump-CGM offerings.

Opportunities

New approvals for closed-loop systems, geographic expansion in Asia Pacific, and cross-selling within existing cardiovascular and hospital customers.

Threats

Competitive pressure from standalone CGM leaders, regulatory delays, cybersecurity and interoperability challenges, and pricing pressures from payors.

CGM Market Regional Competitive Landscape

North America remains the largest revenue pool for CGM market companies, driven by high diabetes prevalence, broad commercial and public reimbursement, and rapid adoption of automated insulin delivery. Dexcom, Abbott, and Medtronic dominate, while emerging players such as Senseonics gain traction in specific, highly engaged patient niches.

In Europe, universal healthcare systems and strong endocrinology networks foster structured CGM adoption, particularly among Type 1 patients. CGM market companies like Dexcom, Abbott, Roche, and A. Menarini Diagnostics compete for tenders and regional contracts, with pricing, evidence of outcomes improvement, and integration into national registries critical for success.

Asia Pacific is the fastest-growing region, with China and India representing substantial underpenetrated populations. POCTech and other regional players compete on affordability, while Dexcom and Abbott expand through localized pricing, manufacturing partnerships, and targeted education. CGM market companies increasingly tailor solutions for diverse healthcare infrastructures and out-of-pocket payment models.

Latin America shows steady CGM uptake despite budget constraints, with Brazil and Mexico leading regional adoption. Abbott’s FreeStyle Libre and Roche leverage strong distribution, while Dexcom selectively targets private insurance and affluent self-pay segments. Successful CGM market companies build hybrid reimbursement models and collaborate closely with diabetes societies.

The Middle East and Africa region remains nascent but strategically important, with rising obesity and diabetes incidence. Wealthier Gulf states invest in advanced CGM and pump technologies from Dexcom, Abbott, and Medtronic, while other markets focus on cost-effective solutions. Education, physician training, and localized service networks are central competitive differentiators for CGM market companies.

CGM Market Emerging Challengers & Disruptive Start-Ups

Emerging Challengers & Disruptive Start-Ups

GlucoSense AI
Disruptor
USA

Developing a cloud-native analytics layer that overlays any CGM brand, delivering AI-driven insulin dosing suggestions and hypoglycemia risk alerts.

OptiGlyx Biotech
Disruptor
Germany

Working on enzyme-optimized sensor chemistries to extend CGM wear time beyond 21 days while improving accuracy in extreme glucose ranges.

NeoBeat Metabolics
Disruptor
India

Offering a low-cost, smartphone-first CGM platform focused on Type 2 diabetics and prediabetics in tier-2 and tier-3 cities.

ClearSkin Glucose
Disruptor
South Korea

Pursuing optical, patch-based non-invasive glucose monitoring targeting wellness, sports performance, and insurance-linked lifestyle programs.

VidaLoop Health
Disruptor
Spain

Building a virtual clinic model combining multi-brand CGM devices with remote endocrinology services and payer-aligned outcomes guarantees.

CGM Market Future Outlook & Key Success Factors (2026-2032)

From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning CGM market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.

Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards CGMmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.

Frequently Asked Questions

Find answers to common questions about this company report.